Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Sandimmun Optoral (cyclosporine A) for primary Sjögren's syndrome
2009-013976-38Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cyclosporine in primary Sjögren's syndrome, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Primary efficacy after 16 weeks and Safety of low-dose cyclosporine A. Started Dec 2009; status: completed.
02
Drugs
cyclosporine
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2009-013976-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013976-38.